# Narration and storyboard draft: Rapamycin and Human Healthspan

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Rapamycin has genuine animal longevity evidence. Late-life treatment extends survival in mice, and some models show functional benefits. The human physical-function claim needs its own evidence. In a forty-person trial of older sedentary adults, weekly commercial rapamycin did not improve the primary chair-stand outcome over matched exercise; sensitivity analyses suggested smaller gains. That is a warning about this regimen, not proof that every dose is ineffective or harmful. PEARL studied forty-eight weeks of compounded rapamycin. Its primary visceral-fat endpoint was null, while selected female leanmass and pain signals came from a small subgroup. Leanmass is not strength, and exploratory questionnaires cannot silently replace the primary endpoint. The compounded formulation also produced lower exposure than commercial drug in a separate comparison. Immune trials have specific positives and a later clinical infection null; neither proves slower human aging. Senolytics target a different pathway and have their own disease-specific trials, preclinical benefits and clinical gaps. Consensus helped organize the literature, but original checks corrected scope, event-risk certainty, dose equivalence and a mouse result cited in the wrong direction. The HSEFv 5.3 primary assessment remains Gamma with moderate confidence: partial support, with no verified positive physical-function crossing for the registered healthy-older-adult intermittent regimen.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.